Kinimmune is a clinical-stage pharmaceutical company developing intratumoral immunostimulants for unlocking the full potential of checkpoint inhibition in solid tumors. Principals of the firm are developing tumor-retentive formulations for local immunostimulation of the tumor microenvironment. By tuning the physical and chemical properties of the firm's lead formulations, stimulation is maximally directed against tumor tissues with minimal systemic exposure. This functionality enables potent doses of the compounds inuse to be delivered with the high control of safety, conferring greater tumor killing with fewer adverse events. The firm's compounds leverage pharmaceutical components with highly established track records and human data. Kinimmunes innovative approach has enabled an expeditious regulatory path that is enabling quick-to-clinic results.
